Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis [0.03%]
LIBERTY PRIME和PRIME2研究的后验证据：Dupilumab亚组应答者的分析
Brian S Kim,Shawn G Kwatra,Gil Yosipovitch et al.
Brian S Kim et al.
Background: Prurigo nodularis (PN) is a complex to manage heterogenous disease with limited available treatments. Patients with PN are usually older, with multiple comorbidities adding to the complexity of their care, fre...
Randomized Controlled Trial
The Journal of dermatological treatment. 2026 Dec;37(1):2626213. DOI:10.1080/09546634.2026.2626213 2026
Comparative effectiveness and safety of phototherapy, cytotoxic agents, and biologics in adults with atopic dermatitis: real-world multicenter cohort data [0.03%]
成人特应性皮炎光疗、细胞毒药物及生物制剂疗效和安全性的真实世界多中心队列数据比较
Amr Molla,Raed Jannadi
Amr Molla
Background: Real-world comparative evidence on systemic agents, phototherapy, and biologics for atopic dermatitis (AD) remains limited. Objective: ...
Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years [0.03%]
关于比马列酮用于头皮、甲和掌跖银屑病疗效对比及其他四年疗效研究
Paolo Gisondi,Boni Elewski,Andreas Pinter et al.
Paolo Gisondi et al.
To investigate bimekizumab efficacy in scalp, nail and palmoplantar psoriasis. In this analysis, data are included from the BE SURE, BE VIVID, BE READY, and BE RADIANT phase 3/3b trials (48-56 weeks) and BE BRIGHT open-...
Comparison of long-term efficacy and safety of different therapeutic approaches for vulvar Lichen sclerosus: a systematic review and meta-analysis [0.03%]
不同治疗方法治疗外阴硬化性苔藓长期有效性和安全性的系统评价和meta分析
Daoyun Li,Yun Xu,Fenghua Zhang
Daoyun Li
Aim: This systematic review and meta-analysis aimed to compare the long-term efficacy and safety of physical therapies (laser and photodynamic therapy) versus conventional topical glucocorticoids for the treatment of vulv...
Clinical characteristics, effectiveness, safety, and predictors of PASI75/90 responses to IL-17 biologics in psoriasis involving special sites: a large real-world cohort study revealing treatment response heterogeneity [0.03%]
生物制剂治疗特殊部位银屑病的临床特征、有效性和安全性及其PASI75/90应答预测因素：一项真实世界大样本队列研究揭示疗效异质性
Fengming Hu,Xinglong Xiong,Yujie Lai et al.
Fengming Hu et al.
Psoriasis affecting special anatomical sites (scalp, face, intertriginous areas, and genitals) poses unique treatment challenges and often shows inadequate responses. This study evaluates the real-world efficacy and safety of IL-17 inhibito...
Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: a randomized, double-blind, placebo-controlled trial [0.03%]
3%米诺地尔溶液用于变性男性面部生发疗效和安全性的随机双盲对照试验
Kantarat Wattanawinitchai,Cherrin Pomsoong,Yanisa Ratanapokasatit et al.
Kantarat Wattanawinitchai et al.
Objectives: Facial hair development is a crucial aspect of gender affirmation for transgender men. Despite testosterone therapy, incomplete facial hair growth remains a common concern. This randomized, double-blind, place...
Randomized Controlled Trial
The Journal of dermatological treatment. 2026 Dec;37(1):2638637. DOI:10.1080/09546634.2026.2638637 2026
Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial [0.03%]
掺钕钇铝石榴石激光联合外用1％阿维A霜治疗玫瑰痤疮红斑的疗效及安全性：随机对照研究
Kristine Heidemeyer,Simone Cazzaniga,Alexandra Junge et al.
Kristine Heidemeyer et al.
Objective: Facial erythema and telangiectasia in rosacea are commonly treated with vascular lasers. Combination with ivermectin 1% cream, may enhance outcomes when combined with laser therapy. This study assesses whether topical ivermectin ...
Randomized Controlled Trial
The Journal of dermatological treatment. 2026 Dec;37(1):2635882. DOI:10.1080/09546634.2026.2635882 2026
Injectable platelet-rich fibrin as a valid therapeutic option for inactive linear morphea (en coup de saber): report of cases [0.03%]
用于治疗不动性线形硬化性皮肤炎(刀砍伤型)的可注射富血小板纤维蛋白的疗效观察报告
Xuechen Ai,Jun He,Pengfei Song et al.
Xuechen Ai et al.
Objectives: Localized scleroderma, also called morphea, is an inflammatory cutaneous disorder characterized by sclerosis of the skin and underlying tissues. Morphea is currently classified into 4 subtypes: limited, genera...
Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions [0.03%]
可溶性Fas配体：被忽视的皮肤病和非皮肤病治疗靶点
Roberta Lotti,Brydon Bennett,Alessandra Marconi et al.
Roberta Lotti et al.
Background: The Fas/Fas Ligand (Fas/FasL) system mediates key physiological and pathological pathways. Therapies targeting this system are currently unavailable due to the complexity of the Fas/FasL pathway and the side e...
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study [0.03%]
杜普利尤单抗治疗中国寻常型银屑病患者的真实世界研究：一项为期24周的前瞻性研究
Zhiwei Zhang,Xi Tan,Zhouwei Wu et al.
Zhiwei Zhang et al.
Aim: Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, has demonstrated efficacy in randomized trials for plaque psoriasis, but real-world data in Asian populations remain limited. This 24-week prospective real-world cohort s...